Agathe Philippot

Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial

Young Keun Kim, A. Walls, D. Veesler, 2022, eClinicalMedicine.